This study generates a novel dataset of associations for disorders such as major depression and schizophrenia, providing a global perspective for their genetic etiology.
The hypothesis that antidepressant response has a relevant genetic component was initially suggested by the observation that this phenotype clusters in families.
How effective are non-invasive brain stimulation techniques on the symptoms of psychiatric disorders? How far has the field come, and what’s next?
This study aimed to assess the attitudes and opinions of clinicians practicing in psychiatry toward pharmacogenomic testing, and in so doing elicits possible barriers and risks to employ this technology in patient care.
This review explores promising novel genetic variants derived from preclinical models of alcohol consumption and dependence, and identifies novel pharmacogenetic targets that facilitate therapeutic intervention for the treatment of alcohol use disorder.
In this perspective article, the authors draw attention toward the pharmacoepigenomic influence of antipsychotic drugs, and distinguish its significance from therapeutic response and schizophrenia pathogenesis.
Both lithium and rapamycin could prevent the secondary nerve cell damage caused by the overproduction of glutamate after a traumatic brain injury.
Insight into the current research areas utilizing stem cell models to provide new evidence of the pathobiology of schizopheria and bipolar disorder, followed by how this can influence the development of new targeted therapies.
Eric Wasserman discusses tells us more about his work, uses for noninvasive brain stimulation, and the potential for neuromodulation in the treatment of neurological disorders.
James Coffman responds to questions from our recent webinar, ‘How chronic stress experienced during early development epigenetically programs adult disease risk’.